About Us

TGV-Therapeutics is a biopharmaceutical company focused on the development of novel drugs that can address unmet clinical needs in the treatment of life-threatening systemic fungal infections.

Our lead product candidate, MYC-053, is a novel, antifungal agent that is structurally distinct from the three main classes of antifungal antibiotics.

The effectiveness of MYC-053 against the currently incurable multidrug-resistant fungal infections is attributed to its distinct chemical structure. We developed MYC-053 as an oral drug primarily for the treatment of harmful fungal diseases in humans

Targeting
Targeting
MYC-053 has a broad spectrum of activity covering key non-albicans Candida species, including multidrug-resistant C. glabrata and C. auris.
Survival
Survival
MYC-053 exhibits potent activity against mulridrug-resistant clinical fungal icolates
Improvement
Improvement
MYC-053 can be used to treat serious or life-threatening fungal infections